JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target Investors may now be focused on ACR-2316 as a way to re-validate the company’s tumor-selection platform, the analyst tells investors in a research note. The firm prefers to wait for initial data from ACR-2316 in the second half of 2025 and more meaningful data in 2026 before recommending the shares. Jones would like to see some “real de-risking clinical data to comfortably” value Acrivon’s biomarker-based selection platform.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating
- Acrivon Therapeutics Reports Q1 2025 Progress and Financials
- Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer
- Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer
- Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)